- Report
- March 2024
- 186 Pages
Global
From €3277EUR$3,374USD£2,827GBP
€3641EUR$3,749USD£3,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- August 2023
- 115 Pages
Global
From €1933EUR$1,990USD£1,667GBP
- Report
- February 2024
- 180 Pages
Global
From €3497EUR$3,600USD£3,016GBP
- Report
- October 2023
- 190 Pages
Global
From €4759EUR$4,900USD£4,106GBP
- Drug Pipelines
- April 2024
- 120 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- September 2021
- 40 Pages
China
From €2525EUR$2,600USD£2,178GBP
- Report
- January 2019
- 212 Pages
Global
From €21368EUR$22,000USD£18,433GBP
- Report
- March 2019
- 195 Pages
Global
From €10679EUR$10,995USD£9,212GBP
- Report
- March 2024
- 78 Pages
Global
From €3500EUR$3,860USD£3,125GBP
- Report
- May 2023
- 103 Pages
Global
From €3500EUR$3,860USD£3,125GBP
Alendronate is a drug used to treat endocrine and metabolic disorders. It is a bisphosphonate, a type of medication that helps to reduce the risk of fractures in people with osteoporosis. Alendronate works by slowing down the breakdown of bone and increasing bone density. It is also used to treat Paget's disease of bone, a condition that causes bones to become weak and brittle. Alendronate is available in both oral and intravenous forms.
Alendronate is a widely used drug in the endocrine and metabolic disorders market. It is prescribed to millions of people worldwide and is one of the most commonly prescribed drugs for osteoporosis. Alendronate is also used to treat other bone-related conditions, such as hypercalcemia and hyperparathyroidism.
Some companies in the Alendronate market include Merck, Novartis, Teva Pharmaceuticals, and Mylan. Show Less Read more
